Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists

Jalal A. Jazayeri, Graeme J. Carroll, Ann B. Vernallis

Research output: Contribution to journalArticle

Abstract

Many cytokines have been implicated in the inflammatory pathways that characterize rheumatoid arthritis (RA) and related inflammatory diseases of the joints. These include members of the interleukin-6 (IL-6) family of cytokines, several of which have been detected in excess in the synovial fluid from RA patients. What makes the IL-6 group of cytokines a family is their common use of the glycoprotein 130 (gp130) receptor subunit, to which they bind with different affinities. Several strategies have been developed to block the pro-inflammatory activities of IL-6 subfamily cytokines. These include the application of monoclonal antibodies, the creation of mutant form(s) of the cytokine with enhanced binding affinity to gp130 receptor and the generation of antagonists by selective mutagenesis of the specific cytokine/gp130 receptor-binding site(s). The rationale for the use of anti-cytokine therapy in inflammatory joint diseases is based on evidence from studies in vitro and in vivo, which implicate major cytokines such as interleukin-1 (IL-1), tumour necrosis factor (TNF)-alpha and IL-6 in RA pathogenesis. In particular, IL-6 subfamily antagonists have a wide range of potential therapeutic and research applications. This review focuses on the role of some of the IL-6 subfamily cytokines in the pathogenesis of the inflammatory diseases of the joints (IJDs), such as RA. In addition, an overview of the recently developed antagonists will be discussed.
Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalInternational Immunopharmacology
Volume10
Issue number1
Early online date3 Oct 2009
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Interleukin-6
Rheumatoid Arthritis
Cytokines
Joint Diseases
Glycoproteins
Therapeutic Human Experimentation
Synovial Fluid
Interleukin-1
Mutagenesis
Tumor Necrosis Factor-alpha
Binding Sites
Monoclonal Antibodies

Keywords

  • animals
  • monoclonal antibodies
  • rheumatoid arthritis
  • binding sites
  • drug design
  • glycoproteins
  • humans
  • immunotherapy
  • interleukin-6
  • site-directed mutagenesis
  • recombinant fusion proteins
  • synovial fluid

Cite this

@article{e82c0110c2cd46fb852ba1a896a9c4f3,
title = "Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists",
abstract = "Many cytokines have been implicated in the inflammatory pathways that characterize rheumatoid arthritis (RA) and related inflammatory diseases of the joints. These include members of the interleukin-6 (IL-6) family of cytokines, several of which have been detected in excess in the synovial fluid from RA patients. What makes the IL-6 group of cytokines a family is their common use of the glycoprotein 130 (gp130) receptor subunit, to which they bind with different affinities. Several strategies have been developed to block the pro-inflammatory activities of IL-6 subfamily cytokines. These include the application of monoclonal antibodies, the creation of mutant form(s) of the cytokine with enhanced binding affinity to gp130 receptor and the generation of antagonists by selective mutagenesis of the specific cytokine/gp130 receptor-binding site(s). The rationale for the use of anti-cytokine therapy in inflammatory joint diseases is based on evidence from studies in vitro and in vivo, which implicate major cytokines such as interleukin-1 (IL-1), tumour necrosis factor (TNF)-alpha and IL-6 in RA pathogenesis. In particular, IL-6 subfamily antagonists have a wide range of potential therapeutic and research applications. This review focuses on the role of some of the IL-6 subfamily cytokines in the pathogenesis of the inflammatory diseases of the joints (IJDs), such as RA. In addition, an overview of the recently developed antagonists will be discussed.",
keywords = "animals, monoclonal antibodies, rheumatoid arthritis, binding sites, drug design, glycoproteins, humans, immunotherapy, interleukin-6, site-directed mutagenesis, recombinant fusion proteins, synovial fluid",
author = "Jazayeri, {Jalal A.} and Carroll, {Graeme J.} and Vernallis, {Ann B.}",
year = "2010",
month = "1",
doi = "10.1016/j.intimp.2009.09.019",
language = "English",
volume = "10",
pages = "1--8",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "1",

}

Interleukin-6 subfamily cytokines and rheumatoid arthritis : role of antagonists. / Jazayeri, Jalal A.; Carroll, Graeme J.; Vernallis, Ann B.

In: International Immunopharmacology, Vol. 10, No. 1, 01.2010, p. 1-8.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Interleukin-6 subfamily cytokines and rheumatoid arthritis

T2 - role of antagonists

AU - Jazayeri, Jalal A.

AU - Carroll, Graeme J.

AU - Vernallis, Ann B.

PY - 2010/1

Y1 - 2010/1

N2 - Many cytokines have been implicated in the inflammatory pathways that characterize rheumatoid arthritis (RA) and related inflammatory diseases of the joints. These include members of the interleukin-6 (IL-6) family of cytokines, several of which have been detected in excess in the synovial fluid from RA patients. What makes the IL-6 group of cytokines a family is their common use of the glycoprotein 130 (gp130) receptor subunit, to which they bind with different affinities. Several strategies have been developed to block the pro-inflammatory activities of IL-6 subfamily cytokines. These include the application of monoclonal antibodies, the creation of mutant form(s) of the cytokine with enhanced binding affinity to gp130 receptor and the generation of antagonists by selective mutagenesis of the specific cytokine/gp130 receptor-binding site(s). The rationale for the use of anti-cytokine therapy in inflammatory joint diseases is based on evidence from studies in vitro and in vivo, which implicate major cytokines such as interleukin-1 (IL-1), tumour necrosis factor (TNF)-alpha and IL-6 in RA pathogenesis. In particular, IL-6 subfamily antagonists have a wide range of potential therapeutic and research applications. This review focuses on the role of some of the IL-6 subfamily cytokines in the pathogenesis of the inflammatory diseases of the joints (IJDs), such as RA. In addition, an overview of the recently developed antagonists will be discussed.

AB - Many cytokines have been implicated in the inflammatory pathways that characterize rheumatoid arthritis (RA) and related inflammatory diseases of the joints. These include members of the interleukin-6 (IL-6) family of cytokines, several of which have been detected in excess in the synovial fluid from RA patients. What makes the IL-6 group of cytokines a family is their common use of the glycoprotein 130 (gp130) receptor subunit, to which they bind with different affinities. Several strategies have been developed to block the pro-inflammatory activities of IL-6 subfamily cytokines. These include the application of monoclonal antibodies, the creation of mutant form(s) of the cytokine with enhanced binding affinity to gp130 receptor and the generation of antagonists by selective mutagenesis of the specific cytokine/gp130 receptor-binding site(s). The rationale for the use of anti-cytokine therapy in inflammatory joint diseases is based on evidence from studies in vitro and in vivo, which implicate major cytokines such as interleukin-1 (IL-1), tumour necrosis factor (TNF)-alpha and IL-6 in RA pathogenesis. In particular, IL-6 subfamily antagonists have a wide range of potential therapeutic and research applications. This review focuses on the role of some of the IL-6 subfamily cytokines in the pathogenesis of the inflammatory diseases of the joints (IJDs), such as RA. In addition, an overview of the recently developed antagonists will be discussed.

KW - animals

KW - monoclonal antibodies

KW - rheumatoid arthritis

KW - binding sites

KW - drug design

KW - glycoproteins

KW - humans

KW - immunotherapy

KW - interleukin-6

KW - site-directed mutagenesis

KW - recombinant fusion proteins

KW - synovial fluid

UR - http://www.scopus.com/inward/record.url?scp=73349112853&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2009.09.019

DO - 10.1016/j.intimp.2009.09.019

M3 - Article

C2 - 19804846

VL - 10

SP - 1

EP - 8

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 1

ER -